Trial reportJournal of diabetes investigation2018
Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.
Trial report in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.Journal of diabetes investigation · 2018Trial
- SGLT2 inhibitors, GLP-1 RAs, and DPP4 inhibitors and the risk of hypomagnesemia in type 2 diabetes: A target trial emulation.PLoS medicine · 2026Article
- Remnant cholesterol in early pregnancy as a predictor of gestational diabetes mellitus beyond triglyceride levels: a retrospective cohort study.BMC pregnancy and childbirth · 2025Article
- Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis.World journal of diabetes · 2025Article
- Effect of oral semaglutide on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy.Diabetology international · 2025Article
- Remnant cholesterol, iron status and diabetes mellitus: a dose-response relationship and mediation analysis.Diabetology & metabolic syndrome · 2024Article
- Association of remnant cholesterol and newly diagnosed early-onset type 2 diabetes mellitus in Chinese population: A retrospective cross-sectional study.Journal of diabetes · 2024Article
- Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.International journal of molecular sciences · 2023Review
- Remnant cholesterol is independently associated with diabetes, even if the traditional lipid is at the appropriate level: A report from the REACTION study.Journal of diabetes · 2023Article
- Remnant cholesterol is independently asssociated with an increased risk of peripheral artery disease in type 2 diabetic patients.Frontiers in endocrinology · 2023Article
- Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study.Journal of clinical medicine · 2022Article
- High remnant cholesterol level is relevant to diabetic retinopathy in type 2 diabetes mellitus.Lipids in health and disease · 2022Observational
- Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation.Journal of diabetes research · 2022Article
- Prognostic Significance of Hypertriglyceridemia in Patients at High and Very High Cardiovascular Risk Depending on the Concentration of Highsensitivity C-reactive Protein.Endocrine, metabolic & immune disorders drug targets · 2022Article
- Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.Cardiovascular diabetology · 2021Review
- Remnant Cholesterol is an Independent Predictor of New-Onset Diabetes: A Single-Center Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use.Journal of diabetes investigation · 2020Article
- Could remnant-like particle cholesterol become a risk factor in diabetic menopausal women with coronary artery disease? A cross-sectional study of single academic center in China.Lipids in health and disease · 2020Article
- Inflammatory Targets in Diabetic Nephropathy.Journal of clinical medicine · 2020Review
- Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionRemnant lipoproteins are thought to be atherogenic. Remnant-like particle cholesterol (RLP-C), which reflects the levels of various kinds of remnant lipoproteins in the blood, has a significant correlation with insulin resistance. MATERIALS AND
methodsIn the present study, we measured the effect of empagliflozin (EMPA) on the levels of RLP-C, and investigated whether EMPA-mediated change in RLP-C is associated with a change in insulin resistance in type 2 diabetes patients who have insulin resistance.
resultsPatients were allocated to receive a placebo (n = 51) or EMPA (n = 58) as an add-on treatment. Fasting blood samples were collected before and 12 weeks after this intervention. EMPA significantly decreased glycated hemoglobin, bodyweight, systolic blood pressure, plasma triglycerides, liver transaminases and estimated glomerular filtration rate, and increased high-density lipoprotein cholesterol. Furthermore, EMPA decreased RLP-C and homeostatic model assessment of insulin resistance. In the placebo group, there were no significant changes in these factors except for slight increases in liver transaminases. Multiple regression analysis showed that the change in homeostatic model assessment of insulin resistance (P = 0.0102) and the change in alanine aminotransferase (P = 0.0301) were significantly associated with the change in RLP-C in the EMPA group. The change in RLP-C significantly correlated with the change in homeostatic model assessment of insulin resistance (Pearson correlation coefficient 0.503, 95% confidence interval 0.199-0.719; P = 0.00241).
conclusionEMPA decreases RLP-C levels, which is closely associated with amelioration of insulin sensitivity in diabetes patients who have insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.